Barry Berger Discusses Cologuard

Video

Barry Berger, MD, Exact Sciences Corporation, discusses Cologuard, an at-home screening for colorectal cancer.

Barry Berger, MD, Exact Sciences Corporation, discusses Cologuard, an at-home screening for colorectal cancer.

Berger says the test is straightforward because it give a positive or negative answer, which is concluded by examining DNA and fecal hemoglobin in the sample that the patients provide. However, patients should know that Cologuard does not use inherited DNA for screening, but instead looks at changes in DNA that are a result of undergoing carcinogenisis.

Related Videos
Meaghan Mooney, B.S.N., RN, OCN, during the Extraordinary Healer interview
Colleen O’Leary, DNP, RN, AOCNS, EBP-C, LSSYB, in an interview with Oncology Nursing News.
Michelle H. Johann, DNP, RN, PHN, CPAN, WTA, in an interview with Oncology Nursing News explaining surgical path cards
Jessica MacIntyre, DNP, MBA, APRN, NP-C, AOCNP, in an interview with Oncology Nursing News
Alison Tray, of Hartford Healthcare, discusses her team's research on a multidisciplinary team approach to manage the cancer drug shortage
Related Content
CTX-009 Plus Paclitaxel Receives Fast Track Designation for Pretreated Biliary Tract Cancer

CTX-009 Plus Paclitaxel Receives Fast Track Designation for Pretreated Biliary Tract Cancer

May 11th 2024
Article

The FDA granted fast track designation to CTX-009 plus paclitaxel for pretreated metastatic or locally advanced biliary tract cancer.

The Vitals

Nicole Gay Shares How She Counsels Patients on Lung Cancer Screenings

November 15th 2023
Podcast

Nicole Gay, APRN-C, shares how nurse navigators can talk to their patients about lung cancer screening.

Nurse Intervention Approach Feasible in Addressing Cancer Symptom Clusters

Nurse Intervention Approach Feasible in Addressing Cancer Symptom Clusters

April 28th 2024
Article

A pilot study proved that a nurse-coordinated approach shows promise in treating more than just 1 symptom among patients with cancer.

The Vitals

ctDNA Monitoring is a Piece of the Puzzle in CRC Treatment

October 31st 2023
Podcast

Holly Chitwood, DNP, FNP-C, AGACNP-BC, explains how circulating tumor DNA monitoring helps providers screen minimal residual disease in individuals with colorectal cancer.

Image of "FDA Approved" in blue and green.

FDA Approves First Radioactive Drug for Children With SSTR-Positive GEP-NETs

April 23rd 2024
Article

Lutetium Lu 177 dotatate was approved by the FDA for children aged 12 years and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.

Survival Benefit Persists at 3 Years With Durvalumab Plus Chemo in Advanced Biliary Tract Cancer

Survival Benefit Persists at 3 Years With Durvalumab Plus Chemo in Advanced Biliary Tract Cancer

April 16th 2024
Article

Superior 3-year survival outcomes were observed with durvalumab plus chemotherapy compared with chemotherapy alone in patients with advanced biliary tract cancer.

© 2024 MJH Life Sciences

All rights reserved.